Community-acquired pneumonia in the elderly - A practical guide to treatment

被引:12
作者
Lieberman, D [1 ]
Lieberman, D [1 ]
机构
[1] Univ Beer Sheva, Soroka Med Ctr, Pulm Unit, IL-84101 Beer Sheva, Israel
[2] Ben Gurion Univ Negev, Fac Hlth Sci, IL-84105 Beer Sheva, Israel
[3] Univ Beer Sheva, Soroka Med Ctr, Geriatr Ward, IL-84101 Beer Sheva, Israel
关键词
D O I
10.2165/00002512-200017020-00002
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 [法学]; 0303 [社会学]; 100203 [老年医学];
摘要
The incidence of community-acquired pneumonia (CAP), an infectious disease, sharply increases among the elderly and the main risk factor for CAP in this age group is chronic comorbidity. The use of the term CAP in the elderly population should be reserved for pneumonia acquired outside of the nursing home setting, since nursing home-acquired pneumonia differs from CAP in terms of its aetiology and clinical manifestations. The main aetiology for CAP is Streptococcus pneumoniae, but atypical pathogens also play an important role as causative agents. The clinical presentations of CAP in the elderly can be different from those in younger patients, and therefore it is important to be aware of and familiar with these differences to avoid unnecessary delays in reaching the correct diagnosis. Imaging is essential to diagnose CAP and to assess its severity. Clinical and laboratory indices can be used to identify elderly patients with CAP who are at low risk for mortality and who can be treated as outpatients. The decision not to hospitalise elderly patients with CAP is contingent on a good clinical condition and the existence of home support systems. The aetiology of CAP cannot be determined on the basis of clinical manifestations, imaging or routine laboratory test results, and the initial antibiotic therapy for elderly patients with CAP should be empirical, based on accepted guidelines. In the light of developments in recent years, elderly patients with CAP, except those who are severely ill, can be treated empirically with once-daily antibiotic monotherapy in the initial phase, using a third-generation fluoroquinolone preparation, such as sparfloxacin, levofloxacin or moxifloxacin, or a new macrolide such as clarithromycin, azithromycin or dirithromycin. In addition to antibiotic therapy, it is critically important to identify and treat the physiological disturbances that accompany CAP as well as decompensation of chronic comorbid conditions. As soon as the patient's condition permits, oral antibiotic therapy should replace intravenous therapy and early discharge from the hospital should be considered. Since influenza and pneumococcus immunisation can reduce morbidity and mortality from CAP, it is important to implement regular immunisation programmes in the primary care setting.
引用
收藏
页码:93 / 105
页数:13
相关论文
共 69 条
[1]
AHKEE S, 1997, SOUTH MED J, V90, P863
[2]
Balfour JAB, 1999, DRUGS, V57, P363
[3]
Community-acquired pneumonia in adults: Guidelines for management [J].
Bartlett, JG ;
Breiman, RF ;
Mandell, LA ;
File, TM .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :811-838
[4]
BROWN RB, 1993, GERIATRICS, V48, P43
[5]
Cassiere HA, 1998, DM-DIS MON, V44, P616
[6]
*CDC, 1991, MMWR-MORBID MORTAL W, V40, P841
[7]
CUNHA BA, 1990, GERIATRICS, V45, P49
[8]
AGING AND RESPIRATORY SYSTEM [J].
DHAR, S ;
SHASTRI, SR ;
LENORA, RAK .
MEDICAL CLINICS OF NORTH AMERICA, 1976, 60 (06) :1121-1139
[9]
Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study [J].
Donowitz, GR ;
Brandon, ML ;
Salisbury, JP ;
Harman, CP ;
Tipping, DM ;
Urick, AE ;
Talbot, GH .
CLINICAL THERAPEUTICS, 1997, 19 (05) :936-953
[10]
Azithromycin - A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections [J].
Dunn, HJ ;
Barradell, LB .
DRUGS, 1996, 51 (03) :483-505